Home
Categories
EXPLORE
True Crime
Comedy
Society & Culture
Business
Sports
TV & Film
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
00:00 / 00:00
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/03/14/bb/0314bb4c-1718-721d-a90c-2f98c3c0500f/mza_7429023474983437447.jpg/600x600bb.jpg
CLOT Conversations
Thrombosis Canada
49 episodes
1 month ago
Send us a text Diagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their f...
Show more...
Medicine
Health & Fitness,
Science,
Life Sciences
RSS
All content for CLOT Conversations is the property of Thrombosis Canada and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Send us a text Diagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their f...
Show more...
Medicine
Health & Fitness,
Science,
Life Sciences
https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/03/14/bb/0314bb4c-1718-721d-a90c-2f98c3c0500f/mza_7429023474983437447.jpg/600x600bb.jpg
Reduced-Dose Apixaban for Cancer-Associated Thrombosis: A New Standard?
CLOT Conversations
15 minutes
7 months ago
Reduced-Dose Apixaban for Cancer-Associated Thrombosis: A New Standard?
Send us a text In this episode of CLOT Conversations, we sit down with Dr. Marc Carrier to explore a groundbreaking study published in the New England Journal of Medicine on reduced-dose apixaban for cancer-associated venous thromboembolism (VTE). Dr. Carrier breaks down the study’s findings, which suggest that a lower dose of apixaban after six months of treatment is just as effective in preventing clot recurrence — and significantly safer in terms of bleeding risk. Tune in for expert insigh...
CLOT Conversations
Send us a text Diagnosing recurrent venous thromboembolism (VTE) remains one of the biggest clinical challenges in thrombosis medicine. In this episode, Dr. Vicky Mai and Dr. Grégoire Le Gal join us to discuss the international PREDICTORS study (JTH, 2025), which evaluated the performance of commonly used clinical decision rules (Wells and Geneva scores) in patients with suspected recurrent VTE. They share why symptoms can be misleading, how residual clots complicate imaging, and what their f...